Clinical Trial Update: The Role of Interleukin-1 Beta Targeted Therapy for Patients Suffering From Allergic Contact Dermatitis [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating interleukin-1 beta targeted therapy for allergic contact dermatitis has completed, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Allergic Contact Dermatitis

Drugs mentioned

• Interleukin-1 beta targeted therapy

Snippet

Sponsor: Herlev and Gentofte Hospital | Conditions: Allergic Contact Dermatitis | Phase 3 | Status: COMPLETED | Results posted: 2025-05-20